Education
About Us
Working with TipRanks
Follow Us
Gh Research Plc (GHRS)
NASDAQ:GHRS
GHRS Stock Chart & Stats
$16.99
-$0.22(-2.41%)
At close: 4:00 PM EST
$16.99
-$0.22(-2.41%)
Day’s Range― - ―
52-Week Range$7.98 - $20.50
Previous CloseN/A
Volume14.35K
Average Volume (3M)528.13K
Market Cap
$1.05B
Enterprise Value$465.24M
Total Cash (Recent Filing)$288.51M
Total Debt (Recent Filing)$582.00K
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Feb 26, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding62,029,396
10 Day Avg. Volume1,159,281
30 Day Avg. Volume528,129
Financial Highlights & Ratios
PEG Ratio-0.91
Price to Book (P/B)2.04
Price to Sales (P/S)0.00
P/FCF Ratio-8.60
Enterprise Value/Market Cap0.44
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.72K
Enterprise Value/Ebitda-10.93
Forecast
1Y Price Target
$30.20Price Target Upside77.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.65
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPhase 2b and open‑label extension data demonstrated rapid, durable remission with infrequent clinic visits and a favorable safety profile, supporting potential market differentiation versus competitors.
Financial RunwayGHRS reported approximately $293.9 million in cash and marketable securities, providing a financial runway to support a planned 2026 pivotal trial.
Regulatory ClearanceFDA lifted the clinical hold on GH001, enabling initiation of a Phase 3 program and removing a major regulatory overhang for the asset.
Bears Say
Clinical Durability And Safety RiskUncertainty about single‑dose durability and risks such as functional unbinding could complicate Phase 3 design and reduce confidence in long‑term treatment benefit.
International Regulatory UncertaintyFDA clearance of the IND does not ensure acceptance by non‑US regulators for the proprietary device, creating potential regulatory uncertainty in other jurisdictions.
Toxicology Data GapRequests from the FDA for additional rat respiratory histology data leave a toxicology question unresolved that could delay broader regulatory approvals.
GH Research News
GHRS FAQ
What was Gh Research Plc’s price range in the past 12 months?
Gh Research Plc lowest stock price was $7.98 and its highest was $20.50 in the past 12 months.
What is Gh Research Plc’s market cap?
Gh Research Plc’s market cap is $1.05B.
When is Gh Research Plc’s upcoming earnings report date?
Gh Research Plc’s upcoming earnings report date is Feb 26, 2026 which is in 39 days.
How were Gh Research Plc’s earnings last quarter?
Gh Research Plc released its earnings results on Nov 06, 2025. The company reported -$0.23 earnings per share for the quarter, beating the consensus estimate of -$0.237 by $0.007.
Is Gh Research Plc overvalued?
According to Wall Street analysts Gh Research Plc’s price is currently Undervalued.
Does Gh Research Plc pay dividends?
Gh Research Plc does not currently pay dividends.
What is Gh Research Plc’s EPS estimate?
Gh Research Plc’s EPS estimate is -0.27.
How many shares outstanding does Gh Research Plc have?
Gh Research Plc has 62,029,396 shares outstanding.
What happened to Gh Research Plc’s price movement after its last earnings report?
Gh Research Plc reported an EPS of -$0.23 in its last earnings report, beating expectations of -$0.237. Following the earnings report the stock price went down -1.325%.
Which hedge fund is a major shareholder of Gh Research Plc?
Currently, no hedge funds are holding shares in GHRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GH Research Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.20 (77.75% Upside)
$30.20 (77.75% Upside)
Blogger Sentiment
Bullish
GHRS Sentiment 70%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 11.5%
Last 30 Days ▲ 11.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
97.55%
12-Months-Change
Fundamentals
Return on Equity
-17.86%
Trailing 12-Months
Asset Growth
51.31%
Trailing 12-Months
Company Description
Gh Research Plc
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
GHRS Stock 12 Month Forecast
Average Price Target
$30.20
▲(77.75% Upside)
Technical Analysis
Relay Therapeutics
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Pharming Group
―
Prime Medicine, Inc.
―
Ownership Overview
―
Insiders
4.65% Mutual Funds
58.71% Other Institutional Investors
35.74% Public Companies and
Individual Investors